Although large randomized, controlled trials, genetic studies, and observational evidence have highlighted the importance of LDL-C and ApoB-lowering in reducing ASCVD outcomes overall, these studies have focused primarily on major adverse cardiovascular events and CAD outcomes.7,48,49 Our results reveal that the ApoB-lowering effect of several clinically approved and clinical trial-stage drug targets is predicted to differ between PAD and CAD, a finding that may have implications for both drug discovery and treatment paradigms. The gene discussed is APOB; the disease is peripheral arterial disease.